BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK (GSK, GSK.L) has started shipping
doses of trivalent influenza vaccines to US healthcare providers and pharmacies
in preparation for the 2024-25 flu season. This immediately follows a licensing
and lot-release approval from the FDA. GSK expects to distribute over 36 million
doses of trivalent influenza vaccines in the US.

The company said both FLULAVAL and FLUARIX will be available in a 0.5mL,
single-dose, pre-filled syringe and are indicated for people six months of age
and older. FLUARIX and FLULAVAL are vaccines indicated for active immunization
for the prevention of disease caused by influenza A subtype viruses and type B
virus contained in the vaccines.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX